Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Revenue (2020 - 2025)

Historic Revenue for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $10.0 million.

  • Janux Therapeutics' Revenue rose 217790.43% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year decrease of 2336.58%. This contributed to the annual value of $10.6 million for FY2024, which is 3099.1% up from last year.
  • Janux Therapeutics' Revenue amounted to $10.0 million in Q3 2025, which was up 217790.43% from $439000.0 recorded in Q3 2024.
  • Janux Therapeutics' Revenue's 5-year high stood at $10.0 million during Q3 2025, with a 5-year trough of $380000.0 in Q1 2021.
  • For the 5-year period, Janux Therapeutics' Revenue averaged around $2.6 million, with its median value being $1.7 million (2021).
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 8255.86% in 2024, then skyrocketed by 217790.43% in 2025.
  • Over the past 5 years, Janux Therapeutics' Revenue (Quarter) stood at $1.6 million in 2021, then soared by 76.05% to $2.8 million in 2022, then fell by 13.5% to $2.5 million in 2023, then crashed by 82.16% to $439000.0 in 2024, then skyrocketed by 2177.9% to $10.0 million in 2025.
  • Its Revenue stands at $10.0 million for Q3 2025, versus $439000.0 for Q3 2024 and $8.9 million for Q2 2024.